To include your compound in the COVID-19 Resource Center, submit it here.

CB-183: Phase II data

Top-line data from the modified intent-to-treat (mITT) population (n=199) of a double-blind, U.S. and Canadian Phase II trial in 209 patients showed

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE